Jefferies analyst Akash Tewari raised the firm’s price target on Horizon Therapeutics (HZNP) to $125 from $101 and keeps a Buy rating on the shares after Horizon confirmed "highly preliminary discussions" with Sanofi (SNY), Amgen (AMGN) and Johnson & Johnson’s (JNJ) Janssen about potentially being acquired. Tewari thinks a deal happens at about $25B-$30B in value and puts about 85% odds on a deal getting done.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HZNP:
- Stocks jump as Fed looks to moderate pace of interest rate hikes; NIO and HZNP in focus
- Horizon (NASDAQ:HZNP) Spikes as Large Players Show Takeover Interest
- Unusually active option classes on open November 30th
- Horizon Therapeutics takeout in $120-$140 range reasonable, says Cowen
- Horizon Therapeutics takeover value could be $135/share, says Wells Fargo